Review: The central role of calcium in the pathogenesis of cardiovascular disease

Journal of Human Hypertension

Volumn 10, Issue 3, 1996, Pages 143-155

  Haller, H ^a,c   Elliott, H L ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Calcium; Cardiovascular disease

Indexed keywords

CALCIUM; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CALCIUM ION; TRANSCRIPTION FACTOR;

CARDIOVASCULAR DISEASE; HUMAN; PHYSIOLOGY; REVIEW; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR SYSTEM; CELL MEMBRANE TRANSPORT; ENDOTHELIUM CELL; ENERGY RESOURCE; GLOMERULOSCLEROSIS; HEART LEFT VENTRICLE HYPERTROPHY; INSULIN RESISTANCE; ISCHEMIA; MACROPHAGE; MONOCYTE; OXYGEN SUPPLY; PATHOGENESIS; PROTEIN SYNTHESIS; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; THROMBOCYTE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

CALCIUM; CARDIOVASCULAR DISEASES; HUMANS;

EID: 0030091975     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Rasmussen H. The calcium messenger system. N Engl J Med 1986; 17: 1094-1100.
2. Reuter H. Modulation of ion channels by phosphorylation and second messengers. NIPS 1987; 2: 168-171.
3. Meldolesi J, Pozzan T. Pathways of calcium influx at the plasma membrane: voltage-, receptor-, and second messenger-operated channels. Exp Cell Res 1987; 17: 271-283.
4. Hofmann F et al. Regulation of the L-type calcium channel. Trends Pharmacol Sci 1987; 8: 393-398.
5. Berridge MJ. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J 1984; 220: 345-360.
6. Carafoli E. Intracellular calcium homeostasis. Ann Rev Biochem 1987; 76: 1713-1719.
7. Nishizuka Y. Protein kinases 5: protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-496.
8. Poeni M, Alderton J, Tsien RY, Steinhardt RA. Changes of free calcium levels with stages of the cell division cycle. Nature Lond 1985; 315: 147-149.
9. Opie LH, du-Toit EF. Postischemic stunning: the two-phase model for the role of calcium as pathogen. J Cardiovasc Pharmacol 1992; 20 (Suppl 5): S1-S4.
10. Marigliano V et al. Hypertension and atherosclerosis in the elderly: pathogenetic common mechanism and intervention strategies. Clin Exp Hypertens 1993; 1 (Suppl 1): 9-29.
11. de-Jonge MC, Traber J. Nimodipine: cognition, aging, and degeneration. Clin Neuropharmacol 1993; 16 (Suppl 1): S25-S30.
12. Lüscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. CRC Press: Boca Raton, 1990, pp 2-45.
13. Palmer RJM, Ashtor DS, Moncada S. Vascular endothelial cells synthesize nitrioxide from L-arginine. Nature 1988; 333: 664-666.
14. Vanhoutte PM, Rubanyi GM, Miller VM. Modulation of vascular smooth muscle contraction by the endothelium. Ann Rev Physiol 1986; 48: 307-320.
15. Lorenzi M, Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus: call for data. Diabetes 1991; 40: 653-659.
16. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 1: 461-463.
17. Guerra R et al. Mechanisms of abnormal endothelium-dependent vascular relaxation in atherosclerosis: Implications for altered autocrine and paracrine functions of EDRF. Blood Vessels 1989; 26: 300-314.
18. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033-1036.
19. Bevilacqua, MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993; 11: 767-804.
20. Berliner JA et al. Minimally modified LDL stimulates monocyte endothelial interactions. J Clin Invest 1990; 85: 1260-1267.
21. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 1991; 90: 119-126.
22. Haller H et al. LDL induces surface expression of vascular adhesion molecule (VCAM) on endothelial cells via activation of protein kinase C. Hypertension 1995; 25: 511-516.
23. Gilcrease MZ, Hoover RL. Examination of monocyte adherence to endothelium under hyperglycemic conditions. Am J Pathol 1991; 139: 1089-1097.
24. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-451.
25. Simionescu M, Simionescu N. Functions of the endothelial cell surface. Annu Rev Physiol 1986; 48: 279-304.
26. Scharf RE, Harker LA. Thrombosis and atherosclerosis: Regulatory role of interactions among blood components and endothelium. Blut 1987; 55: 131.
27. DiCorleto PE, Chisolm GM. Participation of the endothelium in the development of the atherosclerotic plaque. Prog Lipid Res 1986; 25: 3655-3674.
28. Frishman WH, Sonnenblick EH. The calcium antagonist. In: Schlant R, Alexander RW (eds). The Heart. 8th edition. McGraw Hill: New York, 1994: 1291-1308.
29. Neylon CM, Hoyland J, Mason WT, Irvine RF. Spatial dynamics of intracellular calcium in agonist-stimulated vascular smooth muscle cells. Am J Physiol 1990; 259: C675-C686.
30. Haller H et al. Nuclear calcium signalling is initiated by cytosolic calcium surges in vascular smooth muscle cells. Kidney Int 1994; 46: 1653-1662.
31. 2-production in human alveolar macrophages. Am J Physiol 1991; 261: L723-L713.
32. Nicholson AC et al. Dihydropyridine calcium antagonist modulates cholesterol metabolism and eicosanoid biosynthesis in vascular cells. J Cell Biochem 1992; 48: 393-400.
33. Sinzinger H, Fitscha P. Antiatherosclerotic actions of isradipine. J Cardiovasc Pharmacol 1992; 19 (Suppl 3): S29-S31.
34. Bourdillon PDV, Poole-Wilson PA. The effects of verapamil, quiescence and cardioplegia on calcium exchange and mechanical function in ischemic rabbit myocardium. Circ Res 1982; 50: 360-368.
35. Nayler WG. Calciumantagonisten. Springer-Verlag: Berlin, 1990.
36. Frohlich ED. Calcium antagonists as cardioprotective agents. Am J Cardiol 1992; 70: 7I-9I.
37. Gunther J et al. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res Cardiol 1992; 87: 452-460.
38. Lüscher TF et al. Endothelin-induced vasoconstriction and calcium antagonists. J Hum Hypertens 1992; 6 (Suppl 2): 3-8.
39. Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1 induced vasoconstriction in man: reversal by calcium channel blockade but not by nitrovasodilators or EDRF. Circulation 1991; 83: 469-475.
40. Haller H et al. LDL induces surface expression of vascular adhesion molecule (VCAM) on endothelial cells via activation of protein kinase C. Hypertension 1995; 25: 511-516.
41. Tschöpe D et al. Influence of a single dose of nitrendipine on whole platelet activity in healthy subjects. J Cardiovasc Pharmacol 1988; 12 (Suppl 3): S167-S169.
42. Rostagno C et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium distribution, platelet aggregation and thromboxane A2 formation. Thromb Res 1991; 63: 457-462.
43. Haller H et al. Changes in sensitivity to angiotensin II in platelets. J Cardiovasc Pharmacol 1987; 10 (Suppl 10): S44-S46.
44. McDonagh PF, Rauzzino MJ. Stimulated leukocyte adhesion in coronary microcirculation is reduced by a calcium antagonist. Am J Physiol 1993; 265: H476-H483.
45. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am J Cardiol 1993; 71 (6): 21-29.
46. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990. Nature 1993; 362: 801-809.
47. Fleckenstein-Grun G et al. Calcium overload - an important cellular mechanism in hypertension and arteriosclerosis. Drugs 1992; 1: 23-30.
48. Borcherding SM, Meeves SG, Klutman NE, Howard PA. Calcium-channel antagonists for prevention of atherosclerosis. Ann Pharmacother 1993; 27: 61-67.
49. Betz E, Weiss HD, Heinle H, Fotev Z. Calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol 1991; 18 (Suppl 10): S71-S75.
50. Haller H. Calcium antagonists and cellular mechanisms of glomerulosclerosis and atherosclerosis. Am J Kidney Dis 1993; 21: 26-31.
51. Lichtlen PR, Hugenholtz PG, Rafflenbeul W. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial of Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335: 1109-1113.
52. Waters D, Lesperance J, Francetich M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-1953.
53. Dzau VJ, Gibbons GH. Cell biology of vascular hypertrophy in systemic hypertension. Am J Cardiol 1988; 62: 30G-35G.
54. Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Investig 1993; 71 (Suppl 5): S35-S41.
55. Clement DL, De-Buyzere M, Duprez D. Left ventricular function and regression of left ventricular hypertrophy in essential hypertension. Am J Hypertens 1993; 6 (Suppl 7): 14S-19S.
56. Chapman RA. Control of cardiac contractility at the cellular level. Am J Physiol 1983; 245: H535-H547.
57. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham study. J Cardiovasc Pharmacol 1987; 10 (Suppl 6): S135-S140.
58. Messerli FH, Ketelhut R. Left ventricular hypertrophy. How important a risk factor? Cardiovasc Risk Factors 1990; 1: 8-13.
59. Dahlof B. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy. J Hypertens 1993; 11 (Suppl 3): S29-S35.
60. Danser AH et al. Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995; 92: 1387-1388.
61. Fagard R et al. Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 1. Antihypertensive therapy and left ventricular hypertrophy. J Hypertens 1993; 11 (Suppl 6): S27-S29.
62. McGrae-McDermott M, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: Clinical characteristics and drug therapy. Am J Med 1995; 99: 629-635.
63. Salvetti A et al. What effect does blood pressure control have on the progression toward renal failure? Am J Kidney Dis 1993; 21: 10-15.
64. Parving HH, Rossing P. Calcium antagonists and the diabetic hypertensive patient. Am J Kidney Dis 1993; 21: 47-52.
65. Epstein M. Calcium antagonists and the kidney: future therapeutic perspectives. Am J Kidney Dis 1993; 21: 16-25.
66. Leonetti G, Rapelli A. Are there differences in the renal effects of calcium antagonists? J Hypertens 1993; 11 (Suppl 13): S45-S48.
67. Neumayer HH, Gellert J, Luft FC. Calcium antagonists and renal protection. Ren Fail 1993; 15: 353-358.
68. Rodicio JL, Morales JM, Alcazar JM, Ruilope LM. Calcium antagonists and renal protection. J Hypertens 1993; 11 (Suppl 13): S49-S53.
69. Prichard BN, Smith CC, Sen S, Betteridge DJ. Hypertension and insulin resistance. J Cardiovasc Pharmacol 1992; 20 (Suppl 11): S77-S84.
70. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
71. Draznin B. Cytosolic calcium: a new factor in insulin resistance? Diabetes Res Clin Pract 1991; 11: 141-145.
72. 2+-induced inhibition of insulin-stimulated glucose transport. J Biol Chem 1993; 268: 3352-3356.
73. Begum N, Sussman KE, Draznin B. High levels of cytosolic free calcium inhibit desphophorylation of insulin receptor and glycogen synthase. Cell Calcium 1991; 12: 423-430.
74. Draznin B. Cytosolic calcium and insulin resistance. Am J Kidney Dis 1993; 21: 32-38.
75. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension 1995; 26: 869-879.
76. Luft FC, Johnston CI. Are calcium antagonists of value in ameliorating the course of chronic renal disease? Kidney Int 1992; 41 (Suppl 36): S114-S118.
77. Psaty BM et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
78. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
79. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995; 123: 888-889.